In contrast, clinically, inhibitors targeting the CTLA-4 pathway and PD-1/PD-L1 inhibitors exert their clinical effects by antagonizing the respective receptor and unleashing T cells from their inhibitory states, which restores anti-tumor immunity. Here, CD274 is linked to neoplasm.